Skip to main content
Top
Published in: Tumor Biology 3/2013

01-06-2013 | Research Article

RETRACTED ARTICLE: Comparison of hepatocellular carcinoma (HCC), cholangiocarcinoma (CC), and combined HCC-CC (CHC) with each other based on microarray dataset

Author: Lishan Wang

Published in: Tumor Biology | Issue 3/2013

Login to get access

Abstract

Liver carcinomas have been classified into three types: hepatocellular carcinoma (HCC), cholangiocarcinoma (CC), and combined HCC-CC (CHC). We aim to find the common and different characteristic of these three types of liver cancer. The gene expression profiling of HCC, CC, and CHC were compared with each other, and enrichment pathways and processes in these three liver cancers were also identified. Using GSE15765 datasets downloaded from NCBI GEO database, the gene expression profiling of HCC, CC, and CHC were compared with each other (HCC compared with CC, HCC compared with CHC, and CC compared with HCC). Then, the differentially expressed genes (DEGs) were identified in these three groups respectively, and three PPI networks were constructed for DEGs in each group. Subsequently, the clusters in these networks were identified and further analyzed by ClusterONE and MCODE. Finally, gene set enrichment analysis enrichment analysis was performed to illustrate altered pathways and processes for each type of liver cancer. A total of 112, 530, and 64 DEGs were identified in three groups, respectively, and three PPI networks were constructed respectively for the corresponding group. Through the cluster analysis, we found some new differential marker genes for distinguishing the difference between these three types of liver cancer. We also indicated that we can distinguish HCC with CC through altered pathways and processes. Our findings develop new biomarkers for categorizing the primary liver cancer and may improve patient prognosis of these cancers. However, further validation is required since our results were based on microarray data derived from a small sample size.
Literature
1.
go back to reference Yi X, Luk JM, Lee NP, Peng J, Leng X, Guan XY, et al. Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence. Mol Cell Proteomics. 2008;7(2):315–25.CrossRefPubMed Yi X, Luk JM, Lee NP, Peng J, Leng X, Guan XY, et al. Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence. Mol Cell Proteomics. 2008;7(2):315–25.CrossRefPubMed
2.
go back to reference Goodman ZD, Ishak KG, Langloss JM, Sesterhenn IA, Rabin L. Combined hepatocellular–cholangiocarcinoma. A histologic and immunohistochemical study. Cancer. 2006;55(1):124–35.CrossRef Goodman ZD, Ishak KG, Langloss JM, Sesterhenn IA, Rabin L. Combined hepatocellular–cholangiocarcinoma. A histologic and immunohistochemical study. Cancer. 2006;55(1):124–35.CrossRef
3.
go back to reference Kojiro M. Pathology of hepatocellular carcinoma. Mol Genet Liver Neoplasia. 2011;2011:37–48. Kojiro M. Pathology of hepatocellular carcinoma. Mol Genet Liver Neoplasia. 2011;2011:37–48.
4.
go back to reference Ohishi W, Fujiwara S, Cologne JB, Suzuki G, Akahoshi M, Nishi N, et al. Impact of radiation and hepatitis virus infection on risk of hepatocellular carcinoma. Hepatology. 2011;53(4):1237–45.CrossRefPubMed Ohishi W, Fujiwara S, Cologne JB, Suzuki G, Akahoshi M, Nishi N, et al. Impact of radiation and hepatitis virus infection on risk of hepatocellular carcinoma. Hepatology. 2011;53(4):1237–45.CrossRefPubMed
5.
go back to reference Lau WY, Lai ECH, Lau SHY. Management of bile duct injury after laparoscopic cholecystectomy: a review. ANZ J Surg. 2010;80(1–2):75–81.CrossRefPubMed Lau WY, Lai ECH, Lau SHY. Management of bile duct injury after laparoscopic cholecystectomy: a review. ANZ J Surg. 2010;80(1–2):75–81.CrossRefPubMed
6.
go back to reference Lazaridis KN, Gores GJ. Cholangiocarcinoma. In: Hawley CJ, Bosch J, Richter JE, Garcia-Tsao G, Chan FKL, editors. Textbook of clinical gastroenterology and hepatology. 2nd ed. New York: Wiley; 2012. p. 580–5.CrossRef Lazaridis KN, Gores GJ. Cholangiocarcinoma. In: Hawley CJ, Bosch J, Richter JE, Garcia-Tsao G, Chan FKL, editors. Textbook of clinical gastroenterology and hepatology. 2nd ed. New York: Wiley; 2012. p. 580–5.CrossRef
7.
8.
go back to reference Woo HG, Park ES, Cheon JH, Kim JH, Lee JS, Park BJ, et al. Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Cancer Res. 2008;14(7):2056–64.CrossRefPubMed Woo HG, Park ES, Cheon JH, Kim JH, Lee JS, Park BJ, et al. Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Cancer Res. 2008;14(7):2056–64.CrossRefPubMed
9.
go back to reference Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S, et al. Human Protein Reference Database-2009 update. Nucleic Acids Res. 2009;37:D767–72. doi:10.1093/nar/gkn892 (Database issue).CrossRefPubMed Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S, et al. Human Protein Reference Database-2009 update. Nucleic Acids Res. 2009;37:D767–72. doi:10.​1093/​nar/​gkn892 (Database issue).CrossRefPubMed
10.
11.
go back to reference Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3. doi:10.2202/1544-6115.1027. Article3. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3. doi:10.​2202/​1544-6115.​1027. Article3.
12.
go back to reference Derrick TR, Bates BT, Dufek JS. Evaluation of time-series data sets using the Pearson product–moment correlation coefficient. Med Sci Sports Exerc. 1994;26(7):919–28.CrossRefPubMed Derrick TR, Bates BT, Dufek JS. Evaluation of time-series data sets using the Pearson product–moment correlation coefficient. Med Sci Sports Exerc. 1994;26(7):919–28.CrossRefPubMed
13.
go back to reference Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504.CrossRefPubMedPubMedCentral Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504.CrossRefPubMedPubMedCentral
14.
15.
16.
go back to reference Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34(3):267–73.CrossRefPubMed Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34(3):267–73.CrossRefPubMed
17.
go back to reference Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545.CrossRefPubMedPubMedCentral Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545.CrossRefPubMedPubMedCentral
18.
go back to reference Bieker R, Kessler T, Schwöppe C, Padró T, Persigehl T, Bremer C, et al. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience. Blood. 2009;113(20):5019–27.CrossRefPubMed Bieker R, Kessler T, Schwöppe C, Padró T, Persigehl T, Bremer C, et al. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience. Blood. 2009;113(20):5019–27.CrossRefPubMed
19.
go back to reference Papatheodoridis GV, Chung S, Keshav S, Pasi J, Burroughs AK. Correction of both prothrombin time and primary haemostasis by recombinant factor VII during therapeutic alcohol injection of hepatocellular cancer in liver cirrhosis. J Hepatol. 1999;31(4):747–50.CrossRefPubMed Papatheodoridis GV, Chung S, Keshav S, Pasi J, Burroughs AK. Correction of both prothrombin time and primary haemostasis by recombinant factor VII during therapeutic alcohol injection of hepatocellular cancer in liver cirrhosis. J Hepatol. 1999;31(4):747–50.CrossRefPubMed
20.
go back to reference Koizume S, Jin MS, Miyagi E, Hirahara F, Nakamura Y, Piao JH, et al. Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII. Cancer Res. 2006;66(19):9453–60.CrossRefPubMed Koizume S, Jin MS, Miyagi E, Hirahara F, Nakamura Y, Piao JH, et al. Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII. Cancer Res. 2006;66(19):9453–60.CrossRefPubMed
21.
22.
go back to reference Cheng P, Cheng Y, Su MX, Li D, et al. Bicluster and pathway enrichment analysis of HCV-induced cirrhosis and hepatocellular carcinoma. Asi P J Cancer Prevent. 2012;13:3741–5.CrossRef Cheng P, Cheng Y, Su MX, Li D, et al. Bicluster and pathway enrichment analysis of HCV-induced cirrhosis and hepatocellular carcinoma. Asi P J Cancer Prevent. 2012;13:3741–5.CrossRef
23.
go back to reference Seimiya M, Tomonaga T, Matsushita K, Sunaga M, Oh-ishi M, Kodera Y, et al. Identification of novel immunohistochemical tumor markers for primary hepatocellular carcinoma; clathrin heavy chain and formiminotransferase cyclodeaminase. Hepatology. 2008;48(2):519–30.CrossRefPubMed Seimiya M, Tomonaga T, Matsushita K, Sunaga M, Oh-ishi M, Kodera Y, et al. Identification of novel immunohistochemical tumor markers for primary hepatocellular carcinoma; clathrin heavy chain and formiminotransferase cyclodeaminase. Hepatology. 2008;48(2):519–30.CrossRefPubMed
24.
go back to reference Chaerkady R, Harsha H, Nalli A, Gucek M, Vivekanandan P, Akhtar J, et al. A quantitative proteomic approach for identification of potential biomarkers in hepatocellular carcinoma. J Proteome Res. 2008;7(10):4289–98.CrossRefPubMedPubMedCentral Chaerkady R, Harsha H, Nalli A, Gucek M, Vivekanandan P, Akhtar J, et al. A quantitative proteomic approach for identification of potential biomarkers in hepatocellular carcinoma. J Proteome Res. 2008;7(10):4289–98.CrossRefPubMedPubMedCentral
25.
go back to reference Comunale MA, Lowman M, Ronald E, Krakover J, Philip R, Seeholzer S, et al. Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. J Proteome Res. 2006;5(2):308–15.CrossRefPubMed Comunale MA, Lowman M, Ronald E, Krakover J, Philip R, Seeholzer S, et al. Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. J Proteome Res. 2006;5(2):308–15.CrossRefPubMed
26.
go back to reference Ockner RK, Kaikaus RM, Bass NM. Fatty-acid metabolism and the pathogenesis of hepatocellular carcinoma: review and hypothesis. Hepatology. 2005;18(3):669–76.CrossRef Ockner RK, Kaikaus RM, Bass NM. Fatty-acid metabolism and the pathogenesis of hepatocellular carcinoma: review and hypothesis. Hepatology. 2005;18(3):669–76.CrossRef
27.
go back to reference Fan ST, Lo CM, Lai E, Chu KM, Liu CL, Wong J. Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. New Engl J Med. 1994;331(23):1547–52.CrossRefPubMed Fan ST, Lo CM, Lai E, Chu KM, Liu CL, Wong J. Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. New Engl J Med. 1994;331(23):1547–52.CrossRefPubMed
Metadata
Title
RETRACTED ARTICLE: Comparison of hepatocellular carcinoma (HCC), cholangiocarcinoma (CC), and combined HCC-CC (CHC) with each other based on microarray dataset
Author
Lishan Wang
Publication date
01-06-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 3/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0702-6

Other articles of this Issue 3/2013

Tumor Biology 3/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine